We have audited the accompanying balance sheets
of NuLife Sciences, Inc. ("Company") as of September 30, 2016 and 2015 and the related statements of operations, changes
in stockholders' equity (deficit) and cash flows for the years ended September 30, 2016 and 2015. These financial statements are
the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based
on our audits.
We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits
include consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial statements presentation. We believe that our audits provide
a reasonable basis for our opinion.
In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of NuLife Sciences, Inc. as of September 30, 2016 and
2015, and the result of its operations and its cash flows for the years ended September 30, 2016 and 2015 in conformity with accounting
principles generally accepted in the United States of America.
The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the
Company has had minimal revenues and earnings since inception. These conditions, among others, raise substantial doubt about the
Company's ability to continue as a going concern. Management's plans concerning these matters are also described in Note 3, which
includes achieving profitable operations and raising additional funds through financing. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
Share and per share amounts
have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.
The accompanying notes are
an integral part of these financial statements.
Share and per share amounts
have been retroactively adjusted to reflect the increased number of shares resulting from a stock split.
The accompanying notes are
an integral part of these financial statements.
The accompanying notes are
an integral part of these financial statements.
The accompanying notes are
an integral part of these financial statements.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30,
2016 and 2015
NOTE 1 - ORGANIZATION
NuLife Sciences Inc.,
formerly Smoofi, Inc. (the "Company") was incorporated under the laws of the State of Nevada on October 15, 2013. The
Company issued 7,250,000 shares of its common stock to our founder, Derek Cahill, as consideration for the purchase of a business
plan along with a website.
On April 21, 2015, the Board of Directors of the Company approved
a three-for-one forward stock split of the Company's common stock (the “Forward Split”). Accordingly, shareholders
owning shares of the Company's common stock received two additional shares of the Company for each share they owned, and Mr. Cahill’s
7,250,000 shares became 21,750,000 shares. Prior to the Forward Split the Company had 10,128,600 shares issued and outstanding
and following the Forward Split the Company has 31,085,800 shares issued and outstanding.
Online marketplace
and community
The Company's initially-defined
business strategy is to acquire and/or develop and market software and services that will significantly enhance the performance
and functionality of the Internet services used by individuals and by small to medium sized businesses. The Company's products
and services, essentially an online marketplace and community, will use proprietary technology that will enable users, both service
requestors and service providers, to work collaboratively to obtain substantial improvements in performance, reliability and usability.
Service requestors (people or companies requesting a service) name their own price, date and time for any service. A service requestor
can also select qualifying criteria such as number of reviews or review rankings of a service provider. The first service provider
who can provide that service, on that date, at that time and meets the service ranking requirements will get the project. The web
site and the platform, originally titled www.AnytimeJobe.com experienced security issues shortly after it was launched and had
to be taken down to correct the security problems. At the present time the additional programing to eliminate the security problem
has not been completed and the platform is not available online.
Once the security issues
with the platform are resolved, the Company's online marketplace and online community will match up daily job or service requests
and fill market demand for service requests throughout a particular local community, county or city and will connect local resources
with local needs. A goal is to create jobs and provide market value for basic services by aggregating these low cost services within
each local market. This will maximize value for either the person or company requesting the service and for the person or company
providing the service. In other words, service providers will get the best possible price for their service and the party requesting
the service will pay the lowest possible price.
Operations, Consulting
and Advisory Services in the Organ Transplant segment of the Healthcare Industry
On December 30,
2016, the Company announced the completion of an Asset Purchase Agreement to acquire all of the assets (the “Asset Purchase”)
of GandTex, LLC, a Texas limited liability company (“GandTex”). Pursuant to which the Company purchased from GandTex
certain proprietary patents and a related license in respect of a series of procedures and medical techniques focused on advancing
human organ transplant technology which would eliminate the need for an organ or tissue match, and the necessity for anti-rejection
drugs (the “NuLife Process”). Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals,
the Company agreed to provide additional funding for the newly developed procedure, using the patents and License, to conduct tests
of the new procedure on animal (“Animal Trials”) in the aggregate amount of $300,000. In exchange for the Assets, the
Company issued to GandTex 10,000,000 shares of its Series B Convertible Preferred Stock.
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The Company's financial statements
are prepared using the accrual method of accounting. The Company has elected a September 30 fiscal year-end.
Cash Equivalents
For purposes of
the balance sheet and statement of cash flows, the Company considers all highly liquid instruments with maturity of three months
or less at the time of issuance to be cash equivalents.
Stock-based Compensation
The Company follows
ASC 718-10,
Stock Compensation
, which addresses the accounting for transactions in which an entity exchanges its equity
instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based
payment transactions. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity
instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from
subsequent modifications of awards after the grant date must be recognized. The Company has not adopted a stock option plan and
has not granted any stock options. Nonemployee share-based payments are measured at fair value, based on either the fair value
of the equity instrument issued or on the fair value of the services received. We determine the fair value of common stock grants
based on the price of the common stock on the measurement date (which is the earlier of the date at which a commitment for performance
by the counterparty to earn the equity instruments is reached, if there are sufficient disincentives to ensure performance, or
the date at which the counterparty's performance is complete).
Use of Estimates and Assumptions
Preparation of
the financial statements in conformity with accounting principles generally accepted in the United States requires management to
make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from
those estimates. The Company has adopted the provisions of ASC 260.
Loss per Share
The basic loss
per share is calculated by dividing the Company's net loss available to common shareholders by the weighted average number of common
shares during the year. The diluted loss per share is calculated by dividing the Company's net loss available to common shareholders
by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding
is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share
are the same as basic earnings (loss) per share due to the lack of dilutive items in the Company.
Fair Value Measurements and Disclosures
Fair value estimates
discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30,
2016 and 2015. The respective carrying value of certain on-balance-sheet financial instruments, approximate their fair values.
These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and notes payable. Fair values
were assumed to approximate carrying values for these financial instruments because they are short term in nature and their carrying
amounts approximate fair values or they are receivable or payable on demand.
The Company uses
fair value measurements under the three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure
for fair value measures. The three levels are defined as follows:
•
|
Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
|
•
|
Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.
|
•
|
Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.
|
|
|
Fair Value Measurements
Using Fair Value Hierarchy
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Convertible notes (net of discount) – September 30, 2016
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,545
|
|
|
Convertible notes (net of discount) – September 30, 2015
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Derivative liability – September 30, 2016
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
169,221
|
|
|
Derivative liability – September 30, 2015
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
The following table
provides a summary of the changes in fair value of the Company’s Promissory Notes, which are both Level 3 liabilities as
of September 30, 2016:
Balance at September 30, 2015
|
|
$
|
-0-
|
|
Issuance of notes
|
|
|
100,025
|
|
Debt discount on convertible notes
|
|
|
(100,025
|
)
|
Accretion of debt discount
|
|
|
8,545
|
|
Balance September 30, 2016
|
|
$
|
8,545
|
|
The Company determined
the value of its convertible notes using a market interest rate and the value of the derivative liability issued at the time of
the transaction less the accretion. There is no active market for the debt and the value was based on the delayed payment terms
in addition to other facts and circumstances at the end of September 30, 2016 and 2015.
Derivative Financial Instruments
The Company evaluates
our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.
For stock-based derivative financial instruments, the Company uses the Black-Scholes-Merton pricing model to value the derivative
instruments. The classification of derivative instruments, including whether such instruments should be recorded as liabilities
or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance
sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within
12 months of the balance sheet date.
The classification
of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at
the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value
of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current
or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet
date.
The Company estimates
the fair value of these instruments using the Black-Scholes option pricing model and the intrinsic value if the convertible notes
are due on demand.
We have determined
that certain convertible debt instruments outstanding as of the date of these financial statements include an exercise price “reset”
adjustment that qualifies as derivative financial instruments under the provisions of ASC 815-40, Derivatives and Hedging - Contracts
in an Entity’s Own Stock (“ASC 815-40”). Certain of the convertible debentures have a variable exercise price,
thus are convertible into an indeterminate number of shares for which we cannot determine if we have sufficient authorized shares
to settle the transaction with. Accordingly, the embedded conversion option is a derivative liability and is marked to market through
earnings at the end of each reporting period. Any change in fair value during the period recorded in earnings as “Other income
(expense) - gain (loss) on change in derivative liabilities.”
The following table
represents the Company’s derivative liability activity for the period ended:
Balance at September 30, 2015
|
|
$
|
—
|
|
Initial measurement at issuance date of the notes
|
|
|
100,025
|
|
Derivative expense
|
|
|
94,595
|
|
Change in fair value of derivative at period end
|
|
|
(25,399
|
)
|
Balance September 30, 2016
|
|
$
|
169,221
|
|
Income Taxes
Income taxes
are provided in accordance with ASC 740,
Income Taxes
. A deferred tax asset or liability is recorded for all temporary differences
between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from the net
change during the year of deferred tax assets and liabilities.
Deferred tax assets
are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of
the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax
laws and rates on the date of enactment.
No provision was
made for Federal or State income taxes.
Advertising
Advertising will
be expensed in the period in which it is incurred. There have been no advertising expenses for the reporting periods presented.
Intangible Assets
Intangible assets
with finite lives are amortized over their estimated useful life. The Company monitors conditions related to these assets to determine
whether events and circumstances warrant a revision to the remaining amortization period. The Company tests its intangible assets
with finite lives for potential impairment whenever management concludes events or changes in circumstances indicate that the carrying
amount may not be recoverable. The original estimate of an asset's useful life and the impact of an event or circumstance on either
an asset's useful life or carrying value involve significant judgment.
Recently Issued Accounting Pronouncement
s
In August 2014,
the FASB issued ASU No. 2014-15, "Presentation of Financial Statements — Going Concern (Subtopic 205-40), Disclosure
of Uncertainties about an Entity's Ability to Continue as a Going Concern". Continuation of a reporting entity as a going
concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent.
Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Currently,
there is no guidance under U.S. GAAP about management's responsibility to evaluate whether there is substantial doubt about an
entity's ability to continue as a going concern or to provide related footnote disclosures. The amendments in this Update provide
that guidance. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments
require management to assess an entity's ability to continue as a going concern by incorporating and expanding upon certain principles
that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt,
(2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating
effect of management's plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration
of management's plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6)
require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued).
For the period ended September 30, 2016, management evaluated the Company's ability to continue as a going concern and concluded
that substantial doubt has not been alleviated about the Company's ability to continue as a going concern. While the Company continues
to explore further significant sources of financing, management's assessment was based on the uncertainty related to the amount
and nature of such financing over the next twelve months.
In February 2016,
the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840).
ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments
in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early
application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or
entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently
evaluating the impact of this new standard on its consolidated financial statements.
The Company reviewed
all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the SEC and
they did not or are not believed by management to have a material impact on the Company's present or future financial statements.
NOTE 3 – GOING CONCERN
The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying
financial statements, the Company had negative working capital of $609,917 and, having incurred net losses since inception, an
accumulated deficit of $1,211,508 at September 30, 2016.
While the Company
believes that, with adequate financial resources, it will be able to generate revenues from services, including cannabis industry
consulting services, and further developing and launching its marketplace platform, the Company's cash position is not sufficient
to support theses growth plans and daily operations. Management believes that the actions presently being taken to further broaden
and implement its business plan and generate additional services, products and revenue provide the opportunity for the Company
to continue as a going concern. While the Company believes in the viability of its strategy to realize revenues and in its ability
to raise additional funds, there can be no assurances that will ever occur. The Company's ability to continue as a going concern
is dependent upon its ability to obtain adequate financing beyond the limited funding it has received in this fiscal year from
a related party (See Note 7), and achieve profitable operations.
The financial
statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE 4 – PREPAID EXPENSES
During the year
ended September 30, 2015, the Company prepaid certain expenses related to legal expenses. At September 30, 2016 and 2015, $-0-
and $3,165 of these expenses remain to be amortized over the useful life through March 2016.
NOTE 5 – NOTES RECEIVABLE
On January 15,
2016, the Company entered into a secured promissory note in the amount of $46,400 to advance funds to the sellers of certain farm
property in Colorado the Company was seeking to purchase. Closing was subject to financing and other contingencies per a non-binding
Letter of Intent. This note had an interest rate of 8% per annum, with principal and unpaid and accrued interest originally due
on June 30, 2016. On March 31, 2016, the Company entered into Amendment #1 to this note to (i) extend the due date to June 30,
2016, unless the contemplated transaction closes prior thereto, in which case the note will be cancelled, (ii) reduce the principal
to $31,400 to characterize $15,000 of the funds transferred to sellers as a non-refundable earnest money payment and (iii) stipulate
that interest is to accrue on the lower $31,400 principal since inception. On June 30, 2016, the Company entered into Amendment
#2 to this note to (i) extend the due date to September 30, 2016, unless the contemplated transaction closes prior thereto, in
which case the note will be cancelled. On September 30, 2016, the Company determined this note to no longer be collectible. As
such, the principal amount of $31,400, the non-refundable deposit amount of $15,000 and accrued interest in the amount of $2,228
was written off and included in operating expense for the year ended September 30, 2016.
On August 17,
2016, the Company entered into a secured promissory note in the amount of $25,000 to advance funds to the sellers of assets. This note has an interest rate of 8% per annum, with principal and unpaid and accrued interest due on February 17, 2017.
As of September 30, 2016, the total outstanding under this note including accrued interest is $25,241.
NOTE 6 - CONSULTING AGREEMENT
On April 1, 2015, the
Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company will pay
the consultant a monthly fee of $8,500 on the first day of each month with the payment deferred until the Company closes financing
in the amount of $3 million or greater. Additionally, the Company was required to issue the consultant 200,000 shares of common
stock on October 1, 2015. On the date of the consulting agreement entered, April 1, 2015, the shares were valued at $1.00 per share
which was the unadjusted share price prior to three-for-one forward stock split. The shares, which have not been issued as of September
30, 2015 and were recorded under equity - shares to be issued, will be issued in a subsequent period.
During the year
ended September 30, 2015 and 2016, the Company recorded stock based compensation expense in the amount of $217,902 and
$43,098 associated with the vesting of the common stock, respectively.
NOTE 7 – NOTES PAYABLE
As of September
30, 2016, the Company had one note payable issued and outstanding to third party lenders with a total principle of $25,000 and
accrued interest of $12,156. The note was due on June 30, 2015, has an interest rate of 12%. This note remains unpaid. The note
is in default as of September 30, 2016.
As of September
30, 2016, the Company had three notes payable issued and outstanding with a related party with a total principle of $74,500 and
accrued interest of $5,038. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January 14, 2016. February
10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing of a certain
contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The related party for all three notes
is East West Secured Developments, LLC, an Arizona Limited Liability Company of which Mr. Brian Loiselle, a director of and consultant
to the Company, is a managing member. On June 30, 2016, the Company entered into Amendment #1 to these three notes to extend the
due date to the earlier of one week after the closing of a certain contemplated farm property acquisition or October 31, 2016.
The three notes are currently in default. However, the default interest demand of 18% by Mr. Loiselle is being disputed by the
Company due to the lack of provision for default interest in the notes.
NOTE 8 – CONVERTIBLE NOTES
Convertible notes consists of the following:
|
|
September 30,
2016
|
|
September 30,
2015
|
|
|
|
|
|
Convertible note payable, annual interest rate of 8%, convertible into common stock at a variable rate per share and due December 2017.
|
|
$
|
50,025
|
|
|
$
|
-0-
|
|
Convertible note payable, annual interest rate of 10%, convertible into common stock at a variable rate per share and due August 2019.
|
|
|
50,000
|
|
|
|
-0-
|
|
Unamortized debt discount
|
|
|
(91,480
|
)
|
|
|
-0-
|
|
|
|
|
8,545
|
|
|
|
-0-
|
|
Less current portion
|
|
|
-0-
|
|
|
|
-0-
|
|
Convertible debt, net of current portion and debt discount
|
|
$
|
8,545
|
|
|
$
|
-0-
|
|
On September 2, 2016, the
Company amended and restated that certain outstanding promissory note of the Company, dated July 3, 2015, in the principal
amount of $50,025. The replacement convertible promissory note matures on December 31, 2017 and bears interest at the rate of 8%
per annum, and the principal and interest due thereunder may be prepaid at any time. The note, together with all interest as accrued,
is convertible into shares of the Company’s common stock at 50% of the trailing average highest closing bid price of the
Company’s common stock on the date of conversion. As of September 30, 2016, the note balance and accrued interest is $50,025
and $5,033, respectively.
Also on September 2, 2016,
the Company entered into those certain Note Purchase Agreements in connection with the issuance of certain convertible promissory
notes in the aggregate principal amount of $50,000. All of the Purchase Notes mature thirty-six months from the date of issuance
and bear interest at the rate of 10% per annum. Each of the Purchase Notes may be prepaid until the Maturity Date at 110% of the
principal and interest amount outstanding. The Purchase Notes, together with all interest as accrued, are each convertible into
shares of the Company’s common stock at 50% of the trailing average highest closing bid price of the Company’s common
stock on the date of conversion. As of September 30, 2016, the note balances and accrued interest are $50,000 and $658, respectively.
NOTE 9 – DERIVATIVE LIABILITY
During August 2016,
the Company entered into a Loan Agreement with an investor pursuant to which the Company issued a convertible promissory note in
the principal amount of $50,025. The Note is convertible into shares of common stock at an initial conversion price subject to
adjustment as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company’s
common stock at 50% of the trailing average highest closing bid price of the Company’s common stock on the date of conversion.
The Note accrues interest at a rate of 8% per annum and matures on December 31, 2017.
During August 2016,
the Company entered into Loan Agreements with investors pursuant to which the Company issued convertible promissory notes in the
principal amount of $50,000. The Notes are convertible into shares of common stock at an initial conversion price subject to adjustment
as contained in the Note. The note, together with all interest as accrued, is convertible into shares of the Company’s common
stock at 50% of the trailing average highest closing bid price of the Company’s common stock on the date of conversion. The
Notes accrue interest at a rate of 10 per annum and mature on August 1, 2019
Due to the variable
conversion price associated with these convertible promissory notes, the Company has determined that the conversion feature is
considered a derivative liability. The accounting treatment of derivative financial instruments requires that the Company record
the fair value of the derivatives as of the inception date of the Convertible Promissory Note and to adjust the fair value as of
each subsequent balance sheet date.
The initial fair value of the embedded
debt derivative of $194,620 was allocated as a debt discount in the amount of $100,025 and was determined using intrinsic value
with the remainder $94,595 charged to current period operations as interest expenses, loss on derivative. The fair value of the
described embedded derivative was determined using the Black-Scholes Model with the following assumptions:
(1) dividend yield of
|
|
0%;
|
(2) expected volatility of
|
|
243% - 413%,
|
(3) risk-free interest rate of
|
|
0.50% - 0.88%,
|
(4) expected life of
|
|
1-3 years, and
|
(5) fair value of the Company’s common stock of
|
|
$0.11 per share.
|
During the years
ended September 30, 2016 and 2015, the Company recorded the loss (gain) in fair value of derivative and derivative expense in the
amount of $69,196 and $-0-, respectively.
For the years ended
September 30, 2016 and 2015, $8,545 and $-0-, were expensed in the statement of operation as amortization of debt discount related
to above notes and shown as interest expenses, respectively.
The following table
represents the Company’s derivative liability activity for the period ended:
Balance at September 30, 2015
|
|
$
|
–
|
|
Initial measurement at issuance date of the notes
|
|
|
100,025
|
|
Derivative expense
|
|
|
94,595
|
|
Change in fair value of derivative at period end
|
|
|
(25,399
|
)
|
Balance September 30, 2016
|
|
$
|
169,221
|
|
The following table presents the components
of the Company’s derivative financial instruments associated with convertible promissory notes (Notes 8), using the market
price of the common stock and are derived using the Black-Scholes option pricing model measured at fair value on a recurring basis,
using Level 1 and 3 inputs to the fair value hierarchy, at September 30, 2016:
|
|
|
2016
|
|
|
|
2015
|
|
Embedded conversion features
|
|
$
|
–
|
|
|
$
|
–
|
|
Derivative financial instruments
|
|
$
|
–
|
|
|
$
|
–
|
|
These derivative
financial instruments arise as a result of applying
ASC 815 Derivative and Hedging
(“ASC 815”), which requires
the Company to make a determination whether an equity-linked financial instrument, or embedded feature, is indexed to the entity’s
own stock. This guidance applies to any freestanding financial instrument or embedded features that have the characteristics of
a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own stock.
NOTE 10 – SHARE CAPITAL
The Company is
authorized to issue 200,000,000 shares of common stock and 5,000,000 shares of preferred stock. The Company issued 1,500,000 shares
of its common stock to its Mr. Sean Clarke, the Company’s Chief Financial Officer and sole director, as founder shares. The
Company issued 21,750,000 shares of our common stock to Derek Cahill as consideration for the purchase of a business plan along
with a website. The acquisition of the business plan and website was valued at $72,500.
On October 29,
2013, the Company completed a private placement where it issued 5,400,000 shares of its common stock to accredited investors for
$18,000.
On April 16, 2014,
the Company completed a public offering whereby 1,735,800 shares of common stock were sold at $0.042 per share for total gross
proceeds of $72,325.
On April 1, 2015,
the Company entered into a twelve-month consulting agreement with an investor relations firm. Per the agreement, the Company granted
200,000 shares of restricted common stock to the investor relations firm which fully vested on October 1, 2015. The final issuance
resulted in 600,000 shares of restricted common stock due to the three-for-one forward stock split. On the date of the consulting
agreement was entered into, April 1, 2015, the shares were valued at $1.00 per share which was the unadjusted share price prior
to three-for-one forward stock split. The subject shares of common stock were issued on March 29, 2016. During the year ended September
30, 2015, the Company recorded share based compensation expense in the amount of $200,000 associated with the vesting of the common
stock granted. On March 31, 2016, the Company and the investor relations firm entered into Amendment #1 to the consulting agreement
to suspend the monthly fee indefinitely until such time as the Company requests that the services resume.
On April 21, 2015,
the Board of Directors of the Company approved a three-for-one forward stock split of the Company's common stock. Accordingly,
shareholders owning shares of the Company's common stock will receive two additional shares of the Company for each share they
own. The Company had 10,128,600 shares issued and outstanding prior to the forward stock split. At September 30, 2016 and September
30, 2015 the Company has 31,085,800 shares and 30,385,800 shares, respectively, of common stock issued and outstanding. The Company
received notification from the Financial Industry Regulatory Authority (FINRA) on May 7, 2015, that it could proceed with the three-for-one
forward stock split. Additional funds were reallocated from Additional Paid in Capital to the Common Stock account in an amount
equal to the additional par value represented by the additional shares issued under the stock split. All share information presented
in these financial statements and accompanying footnotes has been retroactively adjusted to reflect the increased number of shares
resulting from this transaction.
On August 7, 2015,
the Company granted 100,000 shares of restricted common stock to its chief operating officer. On the date of grant, the shares
were valued at $.61 per share which was the unadjusted closing share price on that date for a fair value of $61,000. The shares
vested over a six-month period; accordingly, during the six months ended March 31, 2016, the Company recorded stock based compensation
expense in the amount of $61,000 associated with vesting of the common stock granted. The subject shares of common stock were issued
on March 29, 2016. During the year ended September 30, 2016, the Company recorded stock based compensation expense in the amount
of $43,098, associated with vesting of common stock granted.
On October 31, 2016,
the Company amended and restated its Articles of Incorporation in the form attached hereto as Exhibit 3.1. The purpose of the amendment
and restatement of the Articles of Incorporation was to:
|
(i)
|
Change the Company’s name from “SmooFi, Inc.” to “NuLife Sciences, Inc.”
|
|
(ii)
|
Symbol change from “SMFI” to “NULF”;
|
|
(iii)
|
Increase the number of authorized shares of Preferred Stock to 25,000,000;
|
|
(iv)
|
Increase the number of authorized shares of Common Stock to 475,000,000;
|
|
(v)
|
Define, with respect to the Preferred Stock, the manner in which the Board may define the powers, preferences, rights, and restrictions thereof.
|
Concurrent with
the Company’s increase of its authorized common and preferred stock, the Company requested and received from, the Financial
Industry Regulatory Authority, approval for a name change from Smoofi, Inc. to NuLife Sciences, Inc., and a symbol change from
“SMFI” to “NULF”. The amended and restated Bylaws of the Company are hereto as Exhibit 3.2.
Also on October
31, 2016, the Company adopted a 2016 Non-Qualified Incentive Stock Compensation Plan (the “Compensation Plan”), and
reserved 7,000,000 shares for issuance from the Compensation Plan. As of the date of this report no shares have been issued from
the Compensation Plan.
On November 1, 2016,
the Company amended and restated its Bylaws, providing for a change in the Company’s name from “SmooFi, Inc.”
to “NuLife Science, Inc.” The amended and restated Bylaws of the Company are hereto as Exhibit 3.2.
On November 1, 2016,
the Board approved the Certificates of Designation to the Company’s Articles of Incorporation in respect of Series A Preferred
Stock and Series B Preferred Stock, to provide for the rights, preferences, and privileges as described Exhibits 3.3 and 3.4 hereto.
NOTE 11 - INCOME TAXES
As of September
30, 2016, the Company had net operating loss carry forwards of approximately $936,186 that may be available to reduce future years'
taxable income through 2036.
|
|
As of
September 30,
2016
|
|
As of
September 30,
2015
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Net operating tax carryforwards
|
|
$
|
365,113
|
|
|
$
|
254,373
|
|
Other
|
|
|
—
|
|
|
|
—
|
|
Gross deferred tax assets
|
|
|
365,113
|
|
|
|
254,373
|
|
Valuation allowance
|
|
|
(365,113
|
)
|
|
|
(254,373
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
—
|
|
|
$
|
—
|
|
Realization of
deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences
and carryforwards are expected to be available to reduce taxable income. Management periodically reviews the likelihood that that
it will be able to recover its deferred tax assets. As the achievement of required future taxable income is uncertain based on
an assessment of all available evidence, the Company recorded a valuation allowance equal to the full amount of its deferred tax
assets as of September 30, 2016 and 2015.
Reconciliation
between the provision for income taxes and the expected tax benefit using the federal statutory rate of 34% and state statutory
rate of 5.0% for 2016 and 2015 is as follows:
|
|
2016
|
|
2015
|
Income tax benefit at federal statutory rate
|
|
|
(34.00
|
)%
|
|
|
(34.00
|
)%
|
State income tax benefit, net of effect on federal taxes
|
|
|
(5.00
|
)%
|
|
|
(5.00
|
)%
|
Valuation allowance
|
|
|
39.00
|
|
|
|
39.00
|
%
|
Effective rate
|
|
|
0.00
|
|
|
|
0.00
|
%
|
NOTE 12 - RELATED PARTY TRANSACTIONS
In
April of 2015 Mr. Brian Loiselle, a former director of the Company, agreed to transfer his ownership interest in a cannabis farm
and related equipment known as the "Tamarack Project", which was the subject of a certain Letter of Intent to which the
Company was a party. In addition, it was proposed that Mr. Cahill sell all of his 21,750,000 shares of the Company to a company
controlled by Mr. Loiselle. The transfer of the Tamarack Project and other projects which Mr. Loiselle offered in substitution
to the Tamarack Project were never completed, and the shares of the Company held by Mr. Cahill never were transferred. Mr. Loiselle induced the Company to make a non-refundable payment of $50,000 in connection with his attempt to purchase
a replacement cannabis farm and property, the “Stroud Farm”, which never closed and the $50,000 was written off in
the year ended September 30, 2015. After giving Mr. Loiselle several extensions of time to perform on his proposed multi-part transaction,
we severed relations with Mr. Loiselle in August 2016. As of September 30, 2016, $53,200 was due to Mr. Loiselle and included as
Due to Related Party which is in dispute as described below.
Effective January
1, 2016, in recognition of the absence of employment and consulting agreements and the time commitment to the Company on the part
Mr. Fred Luke, the Company’s President, and Mr. Sean Clarke, the Company's Chief Financial Officer and sole director, and
Brian Loiselle, a former member of the Board of Directors, respectively, the Board of Directors on March 31, 2016 approved monthly
compensation in the amount of $10,000 to be paid to Mr. Sean Clarke and Brian Loiselle, to be deferred and accrued and only paid
following the Closing of the purchase of the Stroud Farm and at such time as the Company has the necessary financial resources.
Effective April 1, 2016, such monthly compensation was revised from $10,000 to $5,000, but the Board of Directors reaffirmed that
such payment was to be deferred and accrued, and only paid following the Closing of the purchase of the Stroud Farm and at such
time as the Company has the necessary financial resources At September 30, 2016, $120,000 has been accrued and is included in Due
to Related Parties
.
However, the Company severed the relationship with Mr. Loiselle in August 2016 following the failure
of close on the purchase the Stroud Farm and, therefore, the Company is disputing the obligation for payment of these accrued consulting
fees.
As of September 30, 2016,
the Company had three notes payable issued and outstanding with an entity controlled by Mr. Loiselle with a total principle of
$74,500 and accrued interest of $5,038. The three notes, in the amount of $47,000, $15,000 and $12,500, were issued on January
14, 2016. February 10, 2016 and February 29, 2016, respectively. The three notes are due on the earlier of one week after the closing
of a certain contemplated farm property acquisition or July 31, 2016, and have an interest rate of 10%. The related party for all
three notes is EastWest Secured Developments, LLC; an Arizona Limited Liability Company of which Mr. Brian Loiselle, a director
of and consultant to the Company, is a managing member. On June 30, 2016, the Company entered into Amendment #1 to these three
notes to extend the due date to the earlier of one week after the closing of a certain contemplated farm property acquisition or
October 31, 2016.
On
April 22, 2015, the Company and Newport Board Group entered into an Advisory Services Agreement whereby Mr. Donahue would
serve as the Company's Chief Operating Officer. The term of the initial agreement was for 60 days. The Board of Directors approved
by resolution to extend the Agreement with the Newport Board Group on June 9, 2015, but no definitive agreement was signed and
no set termination date was set; however, the resolutions provided for either party to terminate the extension at any time with
30 days' written notice. The monthly fee under the original agreement was $4,000 to be paid monthly for Mr. Donahue to serve as
the Chief Operations Officer and was negotiated and connected to the original proposed transfer of the Tamarack Project to the
Company by Mr. Loiselle. During the year ended September 30, 2016, the Company paid $-0- to Newport Board Group, with an additional
$57,500 of monthly fees deferred and included as Due to Related Party at September 30, 2016. During the year ended September 30,
2015, the Company paid $11,832 to Newport Board Group, with an additional $9,500 of monthly fees deferred and included as Due to
Related Party at September 30, 2015. The Company terminated the extension in September 2016, effective October 15, 2016. The Company
has continued to defer and accrue all additional fees through the date of filing of this Report. On August 7, 2015, the Company
granted 100,000 shares of restricted common stock to Mr. John Donahue, the Company’s former Chief Operations Officer.
As
of September 30, 2016, the Company owed Mr. Clarke and Mr. Luke $60,000 and $5,000, respectively, of accrued and unpaid compensation.
These amounts are included as Due to Related Party at September 30, 2016. During the year ended September 30, 2016 and 2015 the
Company paid Mr. Clarke and Mr. Luke $-0- and $10,000, respectively, as compensation.
NOTE 13 -
CONTINGENCY
As of September 30, 2016,
as described in Note 12, the Company has accrued $53,200 in Due to Related party - Mr. Loiselle
,
note payable of $74,500
and accrued interest of $5,038 due
to EastWest Secured Developments, LLC, an entity controlled by Mr. Brian Loiselle, As of today, the aggregated amount of $132,738
has been in default and past due. On top of the amount accrued by the Company, Mr. Loiselle had demanded for a penalty fee of
$101,235, which is approximately 18% monthly default rate on the amount past due. We believe the penalty fee imposed is invalid
and are currently in dispute with Mr. Loiselle.
NOTE 14 -
SUBSEQUENT EVENTS
On October 3, 2016 the
Company entered into a definitive Asset Purchase Agreement to acquire all of the assets of GandTex, LLC, a Texas limited liability
company (“GandTex”), as disclosed by the Company on Form 8-K on October 17, 2016. The transaction had a soft Closing
on November 30, 2016 with the Assignment to the Company of one of the GandTex patents and a License based upon another patent where
James Gandy was a co-inventor. A final Closing of this transaction occurred on December 30, 2016 with the issuance of ten Million
(10,000,000) shares of the Company’s Series B Convertible Preferred Stock to GandTex LLC. Pursuant to the terms of the Asset Purchase, and upon achieving certain pro-forma goals,
the Company agreed to provide additional funding for the newly developed procedure, using the patents and License, to conduct tests
of the new procedure on animal (“Animal Trials”) in the aggregate amount of $300,000.
On September 16, 2016 we
asked Mr. John Hollister to join our management team as our Chief Executive Officer. Due to the financial constraints of the Company
Mr. Hollister did not accept the offer. However, in October 2016 Mr. Hollister agreed to serve as a consultant, then as our interim
our Chief Executive Officer, pending the completion of the sale the Purchase Notes. There has yet to be a definitive agreement
executed between the Company and Mr. Hollister although we expect to have a final agreement finalized in January 2017.
On November 1, 2016, pursuant
to, and in preparation for, the fulfillment of the Asset Purchase Agreement to acquire all of the assets of GandTex, the Company
formed 2 subsidiaries in the state of Nevada, NuLife BioMed, Inc., and NuLife Technologies, Inc. GandTex is a biomedical company
focused on advancing human organ transplant technology and medical research. The assets being transferred consist of certain proprietary
patents for eliminating the need for an organ or tissue match, and the necessity for anti-rejection drugs, as well as
management of, and historical data for, animal trials conducted by GandTex.
On September 27, 2016,
the Company entered into those four (4) Note Purchase Agreements (collectively, the “Purchase Agreements”) in connection
with the issuance of certain convertible promissory notes, dated October 11, 2016 (collectively, the “Purchase Notes”)
in the aggregate principal amount of $50,000. All of the Purchase Notes are due upon demand, provided however, that the holder
thereof can’t make demand until after Ninety (90) days from the date of issuance (the “Maturity Date”). The Purchase
Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together with all interest as accrued, are each convertible
into shares of the Company’s common stock at 50% of the trailing average highest closing bid price of the Company’s
common stock on the date of conversion. The Purchase Agreements and the Purchase Notes contain representations, warranties, conditions,
restrictions, and covenants of the Company that are customary in such transactions with smaller companies.
The Company executed the
Purchase Agreements and issued the Purchase Notes as described in above. The Purchase Notes may be accelerated by the holders thereof
in the event of default. In addition, the amounts due and payable under the Purchase Notes (and, consequently, the number of shares
of common stock convertible thereunto) may be increased to 150% of the principal and interest amounts of the Purchase Notes. The
Purchase Notes are a direct financial obligation of the Company and are considered a current liability of the Company for accounting
purposes.
From November 18, 2016
to December 3, 2016, the Company entered into eight (8) Note Purchase Agreements (collectively, the “Purchase Agreements”)
in connection with the issuance of certain convertible promissory notes (collectively, the “Purchase Notes”) in the
aggregate principal amount of $540,000. All of the Purchase Notes are due upon demand, provided however, that the holder thereof
can’t make demand until after Ninety (90) days from the date of issuance (the “Maturity Date”). The Purchase
Notes bear interest at the rate of 8% compounded monthly. The Purchase Notes, together with all interest as accrued, are each convertible
into shares of the Company’s common stock at a conversion price of Eleven cents ($0.11) per share. The Purchase Agreements
and the Purchase Notes contain representations, warranties, conditions, restrictions, and covenants of the Company that are customary
in such transactions with smaller companies. Copies of the Purchase Agreements and Purchase Notes are included as an Exhibit hereto.
From November 18, 2016
to December 3, 2016, the Company executed the Purchase Agreements and issued the Purchase Notes as described above. The Purchase
Notes may be accelerated by the holders thereof in the event of default. In addition, the amounts due and payable under the Purchase
Notes (and, consequently, the number of shares of common stock convertible thereunto) may be increased to 150% of the principal
and interest amounts of the Purchase Notes. The Purchase Notes are a direct financial obligation of the Company and are considered
a current liability of the Company for accounting purposes.
In respect of the aforementioned
convertible note issuances of the Company, the note holders are each an “accredited investor” as such term is defined
by rules promulgated by the Securities and Exchange Commission (“SEC”). No solicitation was made and no underwriting
discounts were given or paid in connection with these transactions. The Company believes that the issuance of the convertible promissory
notes pursuant to their respective agreements were exempt from registration with the SEC pursuant to Section 4(2) of the Securities
Act of 1933.
On November 15, 2016, the
Board approved the grant of 1,500,000 common stock purchase options to Fred Luke, the Company’s President, at an exercise
price of not less than One Hundred Ten percent (110%) of the ten (10) day lowest trailing average closing bid price of such shares
on the date of execution of the Option Agreement (the “Option Agreement”) which was Fourteen cents ($0.14) per share
and subject to certain adjustments on November 15, 2016.
Concurrent
with the Company’s filing with the Nevada Secretary of State’s office, the Company requested and received from the
Financial Industry Regulatory Authority, approval for the following:
|
(i)
|
Change the Company’s name from “SmooFi, Inc.” to “NuLife Sciences, Inc.”;
|
|
(i)
|
Symbol change from “SMFI” to “NULF”;
|
|
(ii)
|
Increase the number of authorized shares of Preferred Stock to 25,000,000;
|
|
(iii)
|
Increase the number of authorized shares of Common Stock to 475,000,000; and
|
|
(iv)
|
Define, with respect
to the Preferred Stock, the manner in which the Board may define the powers, preferences, rights, and restrictions thereof.
|
Also on October 31, 2016, the Company
adopted a 2016 Non-Qualified Incentive Stock Compensation Plan (the “Compensation Plan”), and reserved 7,000,000 shares
for issuance from the Compensation Plan. As of the date of this report no shares have been issued from the Compensation Plan.
These
changes to our Articles of Incorporation will enable the Company’s board of directors, without further authorization from
shareholders, to issue up to 475,000,000 shares of common stock and up to 25,000,000 shares of preferred stock having such rights,
privileges, and preferences as determined by the board of directors, for consideration deemed adequate in exchange for such shares.